Concert Pharmaceuticals achieves $2 million milestone for its AVP-786

26 August 2014

USA-based Concert Pharmaceuticals (Nasdaq: CNCE) has achieved a $2 million milestone under its development and license agreement for AVP-786 which it holds with Avanir Pharmaceuticals (Nasdaq: AVNR), the second earned under the agreement.

The milestone payment has been triggered by Avanir initiating dosing in a Phase II clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder. Avanir has worldwide rights to develop and commercialize the treatment and other deuterium-modified dextromethorphan compounds, believed to have potential in the treatment of neurological and psychiatric disorders. Concert is also eligible to receive additional payments upon achieving certain predefined clinical, regulatory and commercial targets.

While Avanir will retain overall responsibility for research, development and commercialization of deuterium-modified dextromethorphan compounds (including AVP-786), Concert is eligible to receive tiered royalties on global sales of ainy products containing them.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK